-
Man Accused of Ramaswamy Death Threat Is Charged With Threatening Christie
Tyler Anderson of New Hampshire was charged on Wednesday with threatening the lives of Chris Christie and another unnamed presidential candidate.
-
Common Travel Mistakes and How to Avoid Them in 2024
Our columnist begs you to avoid middlemen, get promises in writing and stop expecting perfection in an imperfect world.
-
How to Fall in Love with Life Again: 7 Tips
If your life feels like it’s been missing that special spark lately, don’t fret. It is possible to fall in love with life again – and these seven tips will help you get there. Before we dive in, though, let’s get one thing out of the way: there’s no shame in admitting that you’re not…
-
They lived in a van. Here’s their advice on small-space living.
The true masters of minimalist decorating, these modern nomads know how to make every inch work overtime, whether it’s in a home on wheels or a tiny apartment.
-
Why the internet can’t kill holiday cards
In a digital world, the paper Christmas card persists — and tells a story about your family in a way a text never could.
-
Democrats Keep Hoping It’s Curtains for Trump. He’s Still Center Stage.
As Donald Trump faces a new threat to his political future, this time over the question of ballot eligibility, Democrats again find themselves looking toward American institutions to stop him.
-
EYLEA® (aflibercept) and Soliris® (eculizumab) IPR Updates
On December 8, 2023, the PTAB instituted three of Samsung Bioepis’s pending IPRs against Alexion’s Soliris® (eculizumab), IPR2023-00933, IPR2023-00998, and IPR2023-00999. The challenged patents include composition of matter, formulation, and method of treatment claims. Samsung Bioepis filed two additional IPRs in June, IPR2023-01069 and IPR2023-01070, that are awaiting institution decisions….By: Venable LLP
-
The EU Reaches a Political Agreement on the AI Act
On December 8, representatives from the European Commission, the European Parliament, and the Council of the European Union (EU) reached political agreement on the shape and contents of the EU’s AI Act (the “Act”), setting the stage for the EU to implement the world’s first comprehensive AI law. As we have addressed in previous posts,…
-
Year-End Review – Data Privacy Insights To Take into 2024
Privacy and data protection has been a dynamic legal space in 2023. Throughout the year, our team at BakerHostetler worked with hundreds of clients on a wide range of challenging compliance issues. As the year ends, we want to take the opportunity to highlight some key areas we believe are worth particular attention moving into…
-
Celltrion Completes Application for FDA Approval of CT-P41, Biosimilar of Prolia® / Xgeva®
On November 30, 2023, Celltrion announced that it filed for an abbreviated Biologics License Application (aBLA) for FDA approval of CT-P41 (denosumab), a proposed biosimilar of Amgen’s Prolia® / Xgeva® (denosumab)……By: Venable LLP
